-
Mashup Score: 0
Kit Yu Lu, MD, discussed the implications of the TROPiCS-02 and DESTINY-Breast06 trial data for sequencing ADCs in HR+/HER2– breast cancer.
Source: www.cancernetwork.comCategories: General Medicine NewsTweet
-
Mashup Score: 0
Currently, sacituzumab govitecan, T-DXd, and Dato-DXd cannot be compared in HR+/HER2– breast cancer due to a lack of head-to-head trials.
Source: www.cancernetwork.comCategories: General Medicine NewsTweet-
Due to the lack of head-to-head trials, sacituzumab govitecan, T-DXd, and Dato-DXd cannot be compared in HR+/HER2– breast cancer. #bcsm #ONCOLOGY https://t.co/kTsGaxOREh
-
-
Mashup Score: 0Highlighting the DREAM Program for Late-Stage Lung Cancer Treatment - 20 hour(s) ago
In this episode, CancerNetwork® spoke with stage IV lung cancer survivor, Cornelia Tischmacher, and treating thoracic surgeon, Ankit Bharat, MBBS, of Northwe…
Source: www.youtube.comCategories: General Medicine NewsTweet-
📺 In this week's episode, @AnkitBharatMD from @NorthwesternMed discusses a double lung transplant he conducted as part of the DREAM program. The patient also gave her perspective regarding recovery and QOL. #lcsm https://t.co/JSkouVyvXE https://t.co/p6NJ3dx6Yi
-
-
Mashup Score: 0
Given an unmet need for efficacious therapies against ALK-positive NSCLC, experts discuss optimal ALK TKI sequencing for patients with this disease.
Source: www.cancernetwork.comCategories: General Medicine NewsTweet-
ALK-positive lung cancer, which accounts for approximately 4% of lung cancer diagnoses and is generally found in NSCLC, typically impacts younger patients and non-smokers. #lcsm | @MNagasaka https://t.co/jaFNK6Mcrk
-
-
Mashup Score: 1
Tafasitamab is the first CD19 antibody approved in China for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.
Source: www.cancernetwork.comCategories: General Medicine NewsTweet-
The Chinese NMPA approved tafasitamab with lenalidomide followed by tafasitamab monotherapy, for adult patients with relapsed or refractory diffuse large B-cell lymphoma who are ineligible for autologous stem cell transplant. #lymsm #ASCT https://t.co/YisyNPwzgI https://t.co/YSoIEoQC3g
-
-
Mashup Score: 0
“The data, even in fast progressors and within 6 months of endocrine therapy, [show it] is working,” stated Monica Khunger Malhotra, MD.
Source: www.cancernetwork.comCategories: General Medicine NewsTweet-
"Everybody deserves a trial of T-DXd in their metastatic setting," said one expert on treating patients with HER2+/HR- breast cancer. Read the rest of the disucssion here: https://t.co/WLhPkfUepg #bcsm #ONCOLOGY
-
-
Mashup Score: 4
Data from the DREAMM-7 and DREAMM-8 trials support the approval of belantamab mafodotin for patients with relapsed/refractory multiple myeloma in Japan.
Source: www.cancernetwork.comCategories: General Medicine NewsTweet-
Japan’s Ministry of Health, Labour and Welfare approved 2 belantamab mafodotin-based regimens for adult patients with relapsed/refractory multiple myeloma. #mmsm #oncology https://t.co/7ziejZbaIi
-
-
Mashup Score: 1
Findings from the CheckMate 77T study support the approval of this nivolumab-based regimen in the European Union.
Source: www.cancernetwork.comCategories: General Medicine NewsTweet-
The European Commission approved nivolumab plus chemotherapy before surgery followed by adjuvant nivolumab for patients with resectable PD-L1–positive non–small cell lung cancer at a high risk of recurrence. #NSCLC #lcsm https://t.co/Kcx2q7OTg5
-
-
Mashup Score: 5Creating an Accommodating Pediatric Cancer Care Experience - 2 day(s) ago
The pediatric care wing of the Jack & Sheryl Morris Cancer Center is intended to accommodate the physical and emotional needs of younger patients with cancer.
Source: www.cancernetwork.comCategories: General Medicine NewsTweet-
The pediatric care wing of the Jack & Sheryl Morris Cancer Center is built to support the physical and emotional needs of younger patients with cancer. #oncology #pedcsm | @slibutti @DrAEvens https://t.co/Ay2777j6gN
-
-
Mashup Score: 1
No new safety signals were observed with bevacizumab, atezolizumab, carboplatin, and etoposide in extensive-stage small cell lung cancer.
Source: www.cancernetwork.comCategories: General Medicine NewsTweet-
Atezolizumab with bevacizumab, carboplatin, and etoposide met the primary end point of 1-year overall survival for patients with extensive-stage small cell lung cancer. #SCLC #lcsm https://t.co/vNF17hRvQX
-
Kit Yu Lu, MD, discussed the implications of the TROPiCS-02 and DESTINY-Breast06 trial data for sequencing ADCs in HR+/HER2– breast cancer. #bcsm https://t.co/GPh8ckIT8c